What is Base Pair Biotechnologies?
Base Pair Biotechnologies operates at the intersection of bioinformatics and molecular biology, specializing in the discovery and development of high-affinity aptamers. The company provides a comprehensive suite of services, including custom aptamer selection, advanced assay development, and proprietary selection algorithms. By leveraging technologies such as Multiplex SELEX, Base Pair Biotechnologies serves a diverse clientele across the pharmaceutical, diagnostic, and environmental monitoring sectors. Their consultative business model ensures that clients receive tailored, high-performance molecular tools designed to solve complex challenges in drug discovery and clinical diagnostics, effectively positioning the firm as a critical partner in the modern life sciences ecosystem.
How much funding has Base Pair Biotechnologies raised?
Base Pair Biotechnologies has raised a total of $150K across 1 funding round:
Debt
$150K
Debt (2020): $150K with participation from PPP
Key Investors in Base Pair Biotechnologies
PPP
Public-Private Partnership
What's next for Base Pair Biotechnologies?
With the recent influx of capital, Base Pair Biotechnologies is expected to prioritize the scaling of its bioinformatics infrastructure and the expansion of its proprietary selection capabilities. The company will likely focus on deepening its penetration into the drug discovery market, where the demand for high-precision molecular binders continues to rise. Strategic initiatives will likely include the enhancement of its Multiplex SELEX platform to support larger-scale research projects and the potential development of new diagnostic applications. As the firm transitions through this late-stage growth phase, the focus will remain on maintaining its competitive edge through technological innovation and strategic partnerships within the global biotechnology sector.
See full Base Pair Biotechnologies company page
